The Goodwin Life Sciences team advises insitro, a machine learning-enabled drug discovery and development company, on the execution of three strategic agreements with Eli Lilly and Company (Lilly) focused on advancing potential new medicines for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), based on targets identified by insitro using the company’s AI/ML-based platform. This collaboration aims to shift this paradigm by combining insitro's machine learning platforms, particularly directed at early biology discovery, with Lilly’s expertise in cutting-edge drug delivery and metabolic disease biology.
Insitro is a machine learning-enabled drug discovery and development company creating a new approach for target and drug discovery. insitro is uncovering genetic targets and new therapeutic hypotheses, leveraging human and cell data to increase the probability of success. These insights provide the starting point for discovering new molecules, which we either build with our in-house, AI-enabled drug discovery platforms or with partners that extend our impact. With more than $700 million in capital raised to date, insitro is building a "pipeline through platform" with a focus on metabolic disease, neurodegeneration and oncology.
The Goodwin team was led by Erini Svokos and Chris Zhong.
For more details, please read the press release as well as coverage in STAT News and Endpoints News.